Complement factor H (CFH) is a key regulatory protein in the alternative complement pathway, serving as the primary soluble inhibitor of complement activation. This glycoprotein binds to C3b and acts as a cofactor for factor I-mediated cleavage, preventing excessive complement activation on host cell surfaces. CFH plays important roles in immune homeostasis and self-recognition. Mutations or deficiencies are associated with various complement-mediated diseases including atypical hemolytic uremic syndrome and age-related macular degeneration.
The Human complement factor H ELISA Kit (CSB-E08931h) provides quantitative measurement of CFH in human samples using a sandwich assay principle. This kit works with serum, plasma, and tissue homogenates with a detection range of 31.2 ng/mL to 2000 ng/mL and sensitivity of 7.8 ng/mL. The assay requires 50-100 μL sample volume, completes within 1-5 hours, and uses detection at 450 nm wavelength for reliable CFH quantification in research applications.
Application Examples
Note: The following application examples are drawn from a selection of publications citing this product. For additional applications, please refer to the full list of references in the "Citations" section.
This ELISA kit has been used in clinical research studies to measure complement factor H levels in human serum and plasma samples. The applications span cardiovascular health research and cancer biomarker validation studies, where complement factor H serves as a target analyte for disease-related research.
• Cancer biomarker research: Validation of complement factor H as a potential biomarker in colorectal cancer studies comparing early-stage patients, late-stage patients, and healthy controls
• Cardiovascular health studies: Measurement of complement factor H levels in plasma samples as part of comprehensive cardiovascular evaluations alongside other clinical parameters
• Clinical biomarker profiling: Integration into multi-analyte panels for examining complement system components in patient populations undergoing clinical evaluation